Wed, Mar 4, 2015, 7:20 AM EST - U.S. Markets open in 2 hrs 10 mins


% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • alternatepatel alternatepatel Jun 27, 2013 3:13 PM Flag

    Amylin AMLN: Michael King from Roadman & R said it was worth less than 10$, AZN+BMS acquired it for 31$

    Amylin AMLN: Michael King from Roadman & Renshaw said it was worth less than 10$ in march 2012, AZN+BMS acquired it for 31$ in june 2012

    pasting some lines from a bloomberg article on 30th march 2012,

    [...“I don’t understand why you would turn down that bid,” from Bristol-Myers, Michael King, a New York-based analyst at Rodman & Renshaw LLC, said in a telephone interview.
    He said Amylin faces increased competition for insulin- related treatments and also has a debt burden that could deter other potential buyers.
    Amylin has $1.4 billion in net debt, more than 90 percent of biotechnology companies with at least $1 billion in market value, according to data compiled by Bloomberg.
    King recommends investors sell Amylin, which he estimates is worth less than $10 a share....]

    jfriedz87, hopes, speculations, thoughts can be seeded in minds of investors (reminds me of Brad Pitt starer Inception). The recent reuters leak suggested cubist offered 20$, and the analyst quoted in the same article said that 16$ is all OPTR would get, i highly suspect it to be a trick to make big holders sell their positions just a little above 16$, and the buyers take the rest when buyout happens at much higher pps.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
12.78+0.1200(+0.94%)Oct 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.